Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Absolute Antibody Receives £850K ($1.4M) Funding

Published: Tuesday, April 08, 2014
Last Updated: Tuesday, April 08, 2014
Bookmark and Share
Announces commercial launch of next generation engineered antibody products and services.

Absolute Antibody Ltd has announced that it has received £850K ($1.4 million) funding. The investment includes a £100K Smart proof of concept funding award from the Technology Strategy Board and £750K from the founders and a group of business angels.

The investment will be used to accelerate the growth of the business by building up its library of engineered antibodies and manufacturing capacity.

The Company has also announced the commercial launch of its suite of recombinant antibody services and catalogue of engineered antibody products, initially targeted at the research antibody market.

Absolute Antibody has developed a proprietary manufacturing platform based on transient transfection for the production of sequenced and engineered antibodies, AbsoluteAbs (AbAbs).

These engineered antibodies provide a number of benefits over antibodies produced using traditional methods, including ultra-low batch-to-batch variability leading to improved reproducibility of results, and the ability to eliminate undesirable properties or add desirable features.

For example, the binding potential for complement and Fc receptors can be eliminated to minimize background staining and provide cleaner results, while desirable features such as tags for detection and purification can be built into the AbAbs.

The manufacture of AbAbs is fast, inexpensive and animal-free, with 100s of mgs generated within two weeks, versus up to three months required by traditional methods, enabling Absolute Antibody to offer vastly reduced time from order to delivery.

Dr Nick Hutchings, CEO of Absolute Antibody, said: "We would like to thank our investors for supporting the Company. The new funding allows us to accelerate the growth of our products and services. Absolute Antibody’s vision is to engineer antibodies that enable customers to achieve more reproducible and cleaner results, with new types of reagents and new formats. We believe Absolute Antibody will be at the forefront of the coming revolution in the £1.3 billion per year research antibody market.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos